Targeting the programmed cell death protein 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) immunological checkpoint with monoclonal antibodies has provided remarkable success in cancer treatment in recent years (37). Here, PDCD1 is linked to cancer.